Profile data is unavailable for this security.
About the company
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
- Revenue in CHF (TTM)59.76bn
- Net income in CHF14.02bn
- Incorporated1966
- Employees101.47k
- LocationRoche Holding AGGrenzacherstr. 124BASEL 4058SwitzerlandCHE
- Phone+41 9 732354295
- Websitehttp://www.roche.com
Mergers & acquisitions
| Acquired company | ROG:SWX since announced | Transaction value |
|---|---|---|
| GenMark Diagnostics Inc | 17.77% | 1.84bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis AG | 48.40bn | 9.06bn | 179.57bn | 108.00k | 18.39 | 3.15 | 12.52 | 3.71 | 4.01 | 4.01 | 21.40 | 23.45 | 0.4176 | 2.19 | 6.37 | 457,478.70 | 7.82 | 6.41 | 10.39 | 8.01 | 70.65 | 69.39 | 18.73 | 17.79 | 0.6482 | -- | 0.3756 | 81.09 | 2.62 | -0.1838 | 13.02 | 2.84 | -5.91 | 4.69 |
| Roche Holding AG | 59.76bn | 14.02bn | 313.25bn | 101.47k | 22.07 | 8.10 | 16.10 | 5.24 | 16.25 | 16.25 | 69.24 | 44.27 | 0.7103 | 2.28 | 5.12 | 588,922.30 | 17.62 | 14.82 | 26.07 | 22.08 | 71.15 | 71.39 | 24.80 | 20.92 | 0.9106 | 80.51 | 0.266 | 66.01 | -5.11 | 3.91 | 5.91 | 10.03 | 13.84 | 2.36 |
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 31 Dec 2020 | 19.94m | 2.84% |
| The Vanguard Group, Inc.as of 05 Nov 2021 | 18.82m | 2.68% |
| UBS Asset Management Switzerland AGas of 03 Nov 2021 | 11.81m | 1.68% |
| BlackRock Fund Advisorsas of 04 Nov 2021 | 11.53m | 1.64% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2021 | 10.58m | 1.51% |
| Credit Suisse Asset Management (Schweiz) AGas of 31 Oct 2021 | 8.79m | 1.25% |
| Massachusetts Financial Services Co.as of 31 Oct 2021 | 7.60m | 1.08% |
| Z�rcher Kantonalbank (Investment Management)as of 30 Jul 2021 | 6.90m | 0.98% |
| Flossbach von Storch AGas of 30 Sep 2021 | 6.54m | 0.93% |
| BlackRock Advisors (UK) Ltd.as of 04 Nov 2021 | 5.31m | 0.76% |
